Severe rhabdomyolysis temporally associated with SARS-CoV-2 vaccine in an adolescent: a case report

Abstract

vaccine (BNT162b2_V) was approved for use in adolescents 12-15 years old. Since its roll-out, concern has been raised about reports of myocarditis following the vaccine in the adolescent population (6). To our knowledge, there are no published reports of myositis or severe rhabdomyolysis following BNT162b2_V in the pediatric population. We present this rare and potentially serious event following